1β-羟基土木香内酯通过AMPK/SREBP-1c改善非酒精性脂肪性肝炎大鼠肝损伤

doi:10.3870/j.issn.1672-8009.2026.03.009

医学分子生物学杂志 ›› 2026, Vol. 23 ›› Issue (3): 302-307.doi: 10.3870/j.issn.1672-8009.2026.03.009

1β-羟基土木香内酯通过AMPK/SREBP-1c改善非酒精性脂肪性肝炎大鼠肝损伤

常健, 张夏霞, 田利英, 袁芸菲, 李森, 宋枚芳, 吴林霞

邯郸市中心医院消化内科河北省邯郸市,056000

收稿日期:2025-11-29 发布日期:2026-06-01
通讯作者: 吴林霞(E-mail:wulinxia05@163.com)
基金资助:
河北省中医药管理局科研计划项目(No.2024194)

1β-Hydroxyalantolactone Ameliorates Hepatic Injury in Rats with Nonalcoholic Steatohepatitis via AMPK/SREBP-1c Signaling Pathway

CHANG Jian, ZHANG Xiaxia, TIAN Liying, YUAN Yunfei, LI Sen, SONG Meifang, WU Linxia

Department of Gastroenterology,Handan Central Hospital,Handan,Hebei,056000,China

Received:2025-11-29 Published:2026-06-01
Contact: WU Linxia(E-mail:wulinxia05@163.com)
Supported by:
Research Program of Hebei Provincial Administration of Traditional Chinese Medicine(No.2024194)

摘要/Abstract

摘要： 目的探究1β-羟基土木香内酯(1β-hydroxyalantolactone,1β-HA)通过AMPK/SREBP-1c对非酒精性脂肪性肝炎大鼠肝损伤的影响。方法以高脂饲料喂养SD大鼠建立非酒精性脂肪性肝炎模型,灌胃给予12.5、25.0、50.0 mg/kg 1β-HA干预4周。检测血清HDL、TG、ALT、AST水平,肝组织病理,α-SMA,MMP-1,TIMP-1,AMPK,SREBP-1c蛋白,IL-6,TNF-α,IL-1β水平和SOD活性、MDA浓度。结果与模型组比较,1β-HA各剂量组HDL显著升高,TG、AST、ALT显著降低(P<0.05);肝组织脂肪变性、炎性浸润及纤维化程度减轻;α-SMA、TIMP-1、SREBP-1c表达下调,MMP-1、AMPK表达上调(P<0.05);IL-6、TNF-α、IL-1β含量降低;SOD活性升高,MDA浓度降低(P<0.05)。结论 1β-HA可通过激活AMPK、抑制SREBP-1c表达,改善非酒精性脂肪性肝炎肝损伤。

关键词: 1β-羟基土木香内酯, 非酒精性脂肪性肝炎, 脂肪变性, 肝纤维化

Abstract: Objective To investigate the effect of 1β-hydroxyalantolactone(1β-HA)on hepatic injury in rats with nonalcoholic steatohepatitis(NASH)through the AMPK/SREBP-1c signaling pathway. Methods A rat model of NASH was established by feeding with high-fat diet.The rats were administered 1β-HA at doses of 12.5,25.0,and 50.0 mg/kg by oral gavage for 4 weeks.Serum levels of HDL,TG,ALT,and AST were measured.Hepatic histopathology was assessed.The protein expression levels of α-SMA,MMP-1,TIMP-1,AMPK,and SREBP-1c were detected.The levels of IL-6,TNF-α,and IL-1β,as well as SOD activity and MDA concentration,were evaluated. Results Compared with the model group,the 1β-HA treatment groups showed significantly increased HDL levels and decreased TG,AST,and ALT levels(P<0.05);hepatic steatosis,inflammatory infiltration,and fibrosis were alleviated;the expression levels of α-SMA,TIMP-1,and SREBP-1c were down-regulated,while those of MMP-1 and AMPK were up-regulated(P<0.05);the levels of IL-6,TNF-α,and IL-1β were reduced;SOD activity was elevated,and MDA concentration was decreased(P<0.05). Conclusion 1β-HA can ameliorate hepatic injury in NASH by activating AMPK and inhibiting the expression of SREBP-1c.

Key words: 1β-hydroxyalantolactone, nonalcoholic steatohepatitis, steatosis, liver fibrosis

中图分类号:

R285.5

常健, 张夏霞, 田利英, 袁芸菲, 李森, 宋枚芳, 吴林霞. 1β-羟基土木香内酯通过AMPK/SREBP-1c改善非酒精性脂肪性肝炎大鼠肝损伤[J]. 医学分子生物学杂志, 2026, 23(3): 302-307.

CHANG Jian, ZHANG Xiaxia, TIAN Liying, YUAN Yunfei, LI Sen, SONG Meifang, WU Linxia. 1β-Hydroxyalantolactone Ameliorates Hepatic Injury in Rats with Nonalcoholic Steatohepatitis via AMPK/SREBP-1c Signaling Pathway[J]. Journal of Medical Molecular Biology, 2026, 23(3): 302-307.

参考文献

[1] 施淑华,何鲤穗,何道兴,等.过表达CaMKKβ缓解脂肪性肝炎脂质堆积和肝脏氧化损伤机制研究[J].医学分子生物学杂志,2022,19(2):121-126.
SHI S H,HE L S,HE D X,et al.CaMKKβ overexpression alleviates lipid accumulation and liver oxidative damage in non-alcoholic liver disease[J].J Med Mol Biol,2022,19(2):121-126.
[2] 尚东方,赵文霞,赵晨露,等.基于NLRP3/Caspase-1/GSDMD焦亡通路探讨涤浊化瘀方对非酒精性脂肪性肝炎小鼠的影响[J].中华中医药杂志,2024,39(11):6061-6065.
SHANG D F,ZHAO W X,ZHAO C L,et al.Mechanism of Dizhuo Huayu Decoction on nonalcoholic steatohepatitis mouse based on NLRP3/Caspase-1/GSDMD pyroptosis pathway[J].China J Tradit Chin Med Pharm,2024,39(11):6061-6065.
[3] TANG J J,HE Q R,DONG S,et al.Diversity modification and structure-activity relationships of two natural products 1β-hydroxy alantolactone and ivangustin as potent cytotoxic agents[J].Sci Rep,2018,8(1):1722.
[4] 沈晓娟,程磊,刘琳.苍术素调节腺苷酸活化蛋白激酶/沉默信息调节因子1信号通路对白细胞介素-1β诱导软骨细胞自噬和凋亡的影响[J].安徽医药,2024,28(5):899-903,1064.
SHEN X J,CHENG L,LIU L.Effect of atractylodin on IL-1β-induced autophagy and apoptosis of chondrocytes by regulating AMPK/SIRT1 signaling pathway[J].Anhui Med Pharm J,2024,28(5):899-903,1064.
[5] SMITH B K,MARCINKO K,DESJARDINS E M,et al.Treatment of nonalcoholic fatty liver disease:Role of AMPK[J].Am J Physiol Endocrinol Metab,2016,311(4):E730-E740.
[6] SHIMANO H,SATO R.SREBP-regulated lipid metabolism:Convergent physiology-divergent pathophysiology[J].Nat Rev Endocrinol,2017,13(12):710-730.
[7] 刘莹,张会存,段娜,等.茵陈蒿汤对高脂饮食诱导大鼠非酒精性脂肪性肝炎的药效学观察[J].中国实验方剂学杂志,2012,18(13):217-222.
LIU Y,ZHANG H C,DUAN N,et al.Effects of Yinchenhao decoction on non-alcoholic steatohepatitis rats induced by high fat diet[J].Chin J Exp Tradit Med Formulae,2012,18(13):217-222.
[8] 郑桃,田雪飞,胡青松,等.连翘苷对肥胖症大鼠脂代谢紊乱和氧化应激的影响及机制研究[J].医学分子生物学杂志,2023,20(1):78-83.
ZHENG T,TIAN X F,HU Q S,et al.Effect and mechanism of phillyrin on lipid metabolism disorder and oxidative stress in obese rats[J].J Med Mol Biol,2023,20(1):78-83.
[9] 郑佳连,张艳,卢秉久,等.基于PI3K-AKT-mTOR通路探讨泽曲明山复方对大鼠非酒精性脂肪性肝炎模型的影响[J].中华中医药学刊,2024,42(12):117-121,后插41-后插47.
ZHENG J L,ZHANG Y,LU B J,et al.Effect of Zequ Mingshan compound prescription(泽曲明山复方)on mouse model of non-alcoholic steatohepatitis[J].Chin Arch Tradit Chin Med,2024,42(12):117-121,后插41-后插47.
[10] YANG Q,ZHAO H,ZHOU A Z,et al.Preventive and therapeutic effects of compoundGinkgoextract in rats with nonalcoholic steatohepatitis induced by high-fat,high-fructose diet[J].Chin J Hepatol,2016,24(11):852-858.
[11] 廖洪柳,徐海锋,徐维蔓.乙型肝炎肝硬化患者HBV-DNA载量与α-SMA、AFP及肝纤维化的关系[J].中南医学科学杂志,2023,51(6):966-969.
LIAO H L,XU H F,XU W M.Relationship between HBV-DNA load andα-SMA,AFP,liver fibrosis in patients with hepatitis B cirrhosis[J].Med Sci J Cent South China,2023,51(6):966-969.
[12] 虞珊珊,张业婷,王元鹏,等.慢性乙型肝炎患者血清MMP-1、MMP-2、TIMP-1和HIF-1α变化及其临床意义探讨[J].实用肝脏病杂志,2024,27(3):329-332.
YU S S,ZHANG Y T,WANG Y P,et al.Changes of serum MMP-1,MMP-2,TIMP-1 and HIF-1α levels in patients with chronic hepatitis B[J].J Pract Hepatol,2024,27(3):329-332.
[13] 齐书妍,黄华,李永坤,等.莪术醇对非酒精性脂肪性肝大鼠肝功能和肝纤维化的影响及机制[J].中国应用生理学杂志,2021,37(6):611-615,672.
QI S Y,HUANG H,LI Y K,et al.Effects of curcumol on liver function and fibrosis in rats of nonalcoholic fatty liver disease and its mechanism[J].Chin J Appl Physiol,2021,37(6):611-615,672.
[14] GORELOVA I S,SKLYAR L F,MARKELOVA E V,et al.Extracellular matrix condition in case of hcvassociated liver fibrosis[J].Med Immunol,2017,19(1):35-44.
[15] CAI X,FANG C,HAYASHI S,et al.Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice[J].J Gastroenterol,2016,51(8):819-829.
[16] 唐金模,梁惠,王宏国,等.皂术茵陈方治疗非酒精性脂肪性肝炎的临床疗效及对游离脂肪酸和TNF-α的影响[J].中国中西医结合杂志,2016,36(5):544-548.
TANG J M,LIANG H Q,WANG H G,et al.Efficacy of Zaozhu Yinchen recipe for treating non-alcoholic steatohepatitis and its effect on free fatty acid and TNF-alpha[J].Chin J Integr Tradit West Med,2016,36(5):544-548.
[17] NAWAZ R,ZAHID S,IDREES M,et al.HCV-induced regulatory alterations of IL-1β,IL-6,TNF-α,and IFN-γ operative,leading liver en-route to non-alcoholic steatohepatitis[J].Inflamm Res,2017,66(6):477-486.
[18] DAY E A,FORD R J,STEINBERG G R.AMPK as a therapeutic target for treating metabolic diseases[J].Trends Endocrinol Metab,2017,28(8):545-560.
[19] CARNEIRO L,ASRIH M,REPOND C,et al.AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient mice[J].Mol Metab,2017,6(12):1625-1633.
[20] JEONT I,OSBORNE T F.SREBPs:metabolic integrators in physiology and metabolism[J].Trends Endocrinol Metab,2012,23(2):65-72.

1β-羟基土木香内酯通过AMPK/SREBP-1c改善非酒精性脂肪性肝炎大鼠肝损伤

1β-Hydroxyalantolactone Ameliorates Hepatic Injury in Rats with Nonalcoholic Steatohepatitis via AMPK/SREBP-1c Signaling Pathway

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	李玎嘉, 张钰婷, 刘亮明. SIRT1在肝脏疾病中的作用及研究进展[J]. 医学分子生物学杂志, 2026, 23(3): 308-315.
[2]	刘进, 窦琳, 陈皓, 马佳睿, 左慧演, 徐芳芷, 张曦月, 满永, 席超, 黄秀清. 蛋白磷酸酶 4 显性负性突变体介导的活性抑制改善棕榈酸诱导的肝细胞脂性凋亡[J]. 医学分子生物学杂志, 2022, 19(2): 97-104.